LSRNW Translational Support Fund 2018

The Translational Support Fund

The Translational Support Fund will allocate up to £5,000 to directly enhance the translational potential of existing drug discovery research projects.The call is open to all Welsh Universities, although preference will be given to NRN-funded projects.

Projects must fall within the NRN’s current therapeutic remit of infectious diseases, neuroscience and oncology, although other areas of unmet medical and veterinary need will also be considered.

Round 1

The following projects were funded from the first call:

Professor Hoffmann, ADME/toxicology analyses of lead Schistosoma mansoni histone methyltransferase (HMT) inhibitors (Aberystwyth University)

Dr Rodrigues, In vivo testing of GATA-2-specific inhibitors to target leukaemia stem cells (LSCs) in acute myeloid leukaemia (Cardiff University)

Professor Westwell, Anticancer site-specific FAK inhibitors – kinase selectivity profiling (Cardiff University)

Professor Hoffmann, Roboworm IV: Development of a motility image analysis model for newly excysted juvenile Fasciola hepatica(Aberystwyth University)

Dr Lloyd-Evans, Development of a clinical trial of miglustat in the Batten family of childhood epilepsies (Cardiff University)

Professor Sheldon, Exemplification of a novel inhibitor of squalene synthase (MPEX098) to increase skin cell tolerance to bacterial cytolysins (Swansea University)

Professor Dyson, Translation of bacterial mediated therapeutic RNAi of solid tumours by demonstrating PARP inhibition in preclinical trials (Swansea University)

Wioleta Zelek, Targeting the terminal pathway in complement – driven disease (Cardiff University)

Round 2

Four projects were funded from the second call, projects include:

Dr Jones, Modulating effector T-cell metabolism in autoimmunity (Swansea University)

Dr Pertusati, ADME studies of Fingolimod phosphate prodrugs as promising Niemann-Pick disease treatment (Cardiff University)

Dr Richard Clarkson, Derivation of a companion diagnostic for the novel anti-metastatic agent CB1 (Cardiff University)

Dr Richard Stanton, Developing HCMV as a vaccine vector (Cardiff University)